IMMUNOME INC (IMNM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IMNM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IMNM | Chief Executive Officer | 59 | ["significant venture capital experience","public company board experience","extensive experience in the biotechnology and life sciences industry"] | ["Compensation (Chair)","Nominating and Corporate Governance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZBIO | Lead Independent Director | 58 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
James Boylan has served as a member of the Board since October 2023. Mr. Boylan has also served as the Chief Executive Officer of Enavate Sciences, a portfolio company of Patient Square Capital that provides capital and strategic growth support to biotech and life science companies, since May 2022. Previously, Mr. Boylan served as President and Head of Investment Banking at SVB Leerink from May 2009 to April 2021. Mr. Boylan currently serves on the board of directors of Enavate Sciences, Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage biopharmaceutical company, Zenas BioPharma (NASDAQ: ZBIO), a clinical-stage biopharmaceutical company, and Graviton Bio, a clinical-stage biopharmaceutical company. Mr. Boylan was previously a director of CAMP4 Therapeutics (NASDAQ: CAMP), a biopharmaceutical company, until September 2025. Mr. Boylan earned his B.S. in Finance from Lehigh University and his M.B.A. from Columbia University. The Nominating Committee and the Board believe Mr. Boylan is qualified to serve on the Board given his significant venture capital experience, public company board experience and extensive experience in the biotechnology and life sciences industry.